EGFR and non-small cell lung carcinoma: The present study demonstrates that for potentially resectable NSCLC with EGFR mutations, neoadjuvant EGFR-TKI therapy with osimertinib is a safe and feasible treatment strategy, as evidenced by a satisfactory R0 resection rate and low toxicity.